Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022031
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
The non-public offering of shares will not be held for the time being
Announcement of the general meeting of shareholders
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) in 2022
The fourth interim meeting of the Fifth Board of directors in 2022 was held on March 4, which was considered and adopted
The proposal on the company’s compliance with the conditions for non-public development of shares, the proposal on the company’s non-public development of shares in 2022 and other proposals related to the non-public offering of shares were.
The relevant proposals deliberated and adopted by the board of directors still need to be deliberated and voted at the general meeting of shareholders. In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the measures for the administration of securities issuance of listed companies, the detailed rules for the implementation of non-public offering of shares by listed companies and other laws, regulations and normative documents, as well as the articles of association of Hunan Fangsheng Pharmaceutical Co.Ltd(603998) companies and other relevant provisions, Based on the overall work arrangement of the company’s non-public offering and other factors, the board of directors of the company decided not to hold the general meeting of shareholders to consider relevant matters for the time being. When the relevant work and matters are prepared, the board of directors of the company will issue a separate notice of convening the general meeting of shareholders and submit it to the general meeting of shareholders to consider the relevant proposals involved in the non-public offering.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
